May had been a busy month for PharmaShots with an unceasing influx of life science updates.
In our most-read Top 20 section, we published reports on Diagnostic Companies and Medical Device Companies.
Like every month, PharmaShots published reports on Key Biosimilars Events, FDA approvals, and EMA approvals along with the New Drug Designation Report. In the Disease of the Month report, we explored Sjögren’s…
Throughout April PharmaShots was swamped with the heavy traffic of life science updates. As an official media partner to Reuters Events, PharmaShots was present in Barcelona, covering groundbreaking presentations from leading biopharma companies.
Our most-read top 20 section featured reports on Top 20 RNAi Therapeutic Companies, Top 20 Biopharma Deal Terminations of 2023, and Top 20 Biopharma Companies. For…
Following the Reuters Events Pharma USA 2024, PharmaShots brings an engaging conversation with Moreno Perugini, President, of Néstle Health Science. Moreno begins the conversation by highlighting Néstle’s journey to become a full-fledged pharma company through a series of acquisitions and deals.
Moreno recalls Néstle’s transitioning into a pharmaceutical company when the company got the rights for Zenpep,…
Like every month PharmaShots was occupied following the trail of biopharma updates across the globe. PharmaShots as an official media partner to Reuters Events Pharma USA 2024 was physically present covering the groundbreaking presentations of biopharma companies.
Our most-read Top 20 Report was dedicated to Women health Focussing Companies & IPOs by Total Fund Value. In the Top-Performing Drug Edition…
Every month PharmaShots explores a new theme to add character and depth to our magazine. March 2024 edition is exploring Precision medicine as a theme. Imbued with curated themes delving deep into assorted segments designed to keep you hooked throughout the magazine. PharmaShots magazine also provides a glimpse of our monthly activities to keep you up-to-date…
Shots:
Our recent Spotlight interview with David Esposito, CEO at ONL therapeutics became a major hit on the internet. We were moved by the overwhelming response from the netizens
Here we have again, David Esposito in an engaging conversation with PharmaShots. David discusses in great length about the company’s lead candidate ONL1204, currently being evaluated…
Shots:
In an extended cut to our Spotlight Interview, PharmaShots presents an exclusive interview session with David A. Dodd, Chairman, President, and CEO at GeoVax labs
David speaks about the company’s rich history and highlights the journey through the years and the strategic shift from being a single-focus HIV vaccine developing company to an infectious…
Spotlight Interview: David A. Dodd, CEO at GeoVax Labs, in an Engaging Conversation with PharmaShots
PharmaShots’ Spotlight offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people.
This week at the Spotlight, we had a riveting discussion with David A. Dodd, Chairman, President & CEO, at GeoVax Labs.
David eloquently highlighted GeoVax’s extraordinary journey over the years from…
“Spotlight-Company of the Month” offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people.
This month at PharmaShots’ Spotlight, we had an opportunity to engage in conversation with David Esposito CEO at ONL Therapeutics.
David discusses the company's lead candidate ONL1204, which is…
PharmaShots February Edition magazine explores the elements of dealmaking in the life sciences and healthcare sector. The magazine unfolds an engaging article followed by illustrative infographics and illuminating BioTrends. The magazine sheds light on key regulatory updates and also includes a few amazing facts on collaboration deals, and mergers & acquisitions.
PharmaShots welcomed the year…

